Lisata extends cash runway from Q3 2026 to Q4 2026

LISATA THERAPEUTICS, INC.

Company now expects current cash to fund operations into Q4 2026, versus prior Q3 2026 estimate.
As of March 31, 2025, cash, cash equivalents and marketable securities were approximately $25.8 million.
Revised guidance based on existing and planned activities; no other material changes disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.